Ivax Launch Of Generic Neurontin Raises Eyebrows
Ivax Corp.'s decision Wednesday to launch a generic version of Pfizer Inc.'s blockbuster epilepsy drug Neurontin in the midst of a drawn-out patent dispute is seen by analysts as a bold...To view the full article, register now.
Already a subscriber? Click here to view full article